Application note: Improved RP-HPLC to analyse intact mAb’s
Posted: 11 March 2021 | Merck | No comments yet
A fast, high-resolution, and reproducible reverse phase HPLC method using the BIOshell™ A400 Protein C4 column to analyse the intact mAb Trastuzumab.
This application note demonstrates that the BIOshell™ A400 Protein C4 column, based on a wide-pore (400 Å) Fused-Core® particle design, is ideally suited for separating the intact therapeutic monoclonal antibody (mAb) Trastuzumab. The retention time, area precision, quantification, and robustness make this RP-HPLC method ideal for biopharma QC. The method can also be used to monitor degraded product created by heat stress, making it suitable for stability studies.
Related content from this organisation
- Formulation development outsourcing market to be worth over $60bn by 2030
- Pursuing new paths in targeted protein degradation drug development
- Efficient shutdown recovery: leveraging RMM to unlock value and ensure environmental quality
- Improved outcome for prostate cancer patients in Phase III PROpel trial
- Testing non-inferiority for accuracy of quantitative microbiological methods
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
